Clinically, DPP-4 inhibitors, a class of oral hypoglycemics that block DPP-4 activity, increase GLP-1 concentrations and are used to treat type 2 diabetes mellitus [7]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.